Answers are grounded in this paper and cite their sources.
S100A1 is a member of the S100 family of Ca 2+ -binding proteins and regulates several cellular processes, including those involved in Ca 2+ signaling and cardiac and skeletal muscle function. In Alzheimer's disease, brain S100A1 is overexpressed and gives rise to disease pathologies, making it a potential therapeutic target. The 2.25 Å resolution crystal structure of Ca 2+ -S100A1 is solved here and is compared with the structures of other S100 proteins, most notably S100B, which is a highly homologous S100-family member that is implicated in the progression of malignant melanoma. The observed structural differences in S100A1 versus S100B provide insights regarding target protein-binding specificity and for targeting these two S100 proteins in human diseases using structure-based drug-design approaches.
No takes yet. Share an insight, caveat, or question.
Melville et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: